- Home
- AEF vs ALDX Comparison
AEF vs ALDX Comparison
Compare AEF & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEF | ALDX |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.1M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AEF | ALDX |
|---|---|---|
| Price | $7.90 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 92.5K | ★ 794.7K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | $8.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.40 | $1.14 |
| 52 Week High | $5.53 | $7.20 |
Technical Indicators
Market Signals| Indicator | AEF | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 52.62 |
| Support Level | $7.64 | $4.92 |
| Resistance Level | $8.01 | $5.60 |
| Average True Range (ATR) | 0.14 | 0.38 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 72.54 | 52.63 |
Price Performance
Historical ComparisonAbout AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.